Granulomatous hyperinflammatory state induced by dupilumab treatment for eosinophilic esophagitis.

We present the first case of a dupilumab-induced hyperinflammatory state in the setting of underlying eosinophilic esophagitis characterized by multisystem granulomatous inflammation. Although clinical trial data and subsequent real-world experience support dupilumab as a highly effective therapy for eosinophilic esophagitis, close monitoring for development of adverse symptoms following initiation remains paramount.
Competing Interests: Disclosure of potential conflict of interest: A. B. Muir receives consulting fees from Bristol-Meyers Squib, Nexstone Immunology, and 10.13039/100009857Regeneron, as well as research funding from 10.13039/100030947Allakos and Morphic. The rest of the authors declare that they have no relevant conflicts of interest.
(© 2024 The Authors.)